Hepatitis C therapy with HCV NS5B polymerase inhibitors
Authors:
- Vincent SorianoVSVincent Soriano
- Eugenia VispoEVEugenia Vispo
- Carmen de MendozaCMCarmen de Mendoza
- Pablo LabargaPLPablo Labarga
- Jose Vicente Fernandez-MonteroJFJose Vicente Fernandez-Montero
- Eva PovedaEPEva Poveda
- Ana TreviñoATAna Treviño
- Pablo BarreiroPBPablo Barreiro
- 27 April 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 14 (9) , 1161-1170
Abstract
Several HCV polymerase inhibitors are in advanced stages of clinical development. They are nucleos(t)ide and non-nucleoside analogs. Nucleos(t)ides inhibit viral replication acting as chain terminators whereas non-nucleosides block allosterically the HCV polymerase. Sofosbuvir is an uridine analog and currently the most promising HCV polymerase inhibitor, being active across all HCV genotypes. It has good tolerability and a robust barrier to resistance. In contrast, non-nucleoside analogs have low to moderate antiviral potency, a low barrier to resistance and inhibit only HCV genotype 1. Studies conducted with distinct HCV polymerase inhibitors as part of interferon-free combinations have opened a new landscape in which shorter treatment duration and all-oral regimens are envisioned as the future curative treatment for most chronic hepatitis C patients. Antiviral drug development for HCV is progressing at a feverish pace. Amongst HCV polymerase inhibitors, sofosbuvir has positioned as unique companion with ribavirin as therapy for most HCV genotypes 2 or 3, and along with NS5A inhibitors for other HCV genotypes. Non-nucleoside HCV polymerase inhibitors are being developed only as part of all-oral combinations with protease inhibitors. The expected high cost of DAAs will preclude their prompt and wider use, allowing room for using alternative cheaper options in easier-to-treat patient populations.Keywords
This publication has 25 references indexed in Scilit:
- Nucleoside/Nucleotide Analogue Polymerase Inhibitors in DevelopmentClinics in Liver Disease, 2013
- Non-nucleoside Analogue Polymerase Inhibitors in DevelopmentClinics in Liver Disease, 2013
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis CNew England Journal of Medicine, 2013
- The changing face of hepatitis C in the new era of direct-acting antiviralsAntiviral Research, 2013
- What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?Current Gastroenterology Reports, 2012
- Interferon-Free Hepatitis C TherapyDrugs, 2012
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C VirusAntimicrobial Agents and Chemotherapy, 2012
- Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic reviewJournal of Hepatology, 2012
- 61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3Journal of Hepatology, 2011
- Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2010